{"entity":{"type":"insider","cik":"0001431819","url":"/insider/0001431819","json_url":"/insider/0001431819.json","name":"ProQuest Associates IV LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":124,"n_filings":34,"first":"2009-12-18","last":"2017-11-29","span_basis":"filed_date"},"name_variants":[{"name":"ProQuest Associates IV LLC","source":"filing","n_filings":34,"first_seen":"2009-12-18","last_seen":"2017-11-29"}],"transactions":[{"id":4693592,"accession":"0000932440-17-000088","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000932440-17-000088","line_url":"/filing/0000932440-17-000088#line-2","is_derivative":false,"issuer_cik":"0001033508","issuer_name":"UroGen Pharma Ltd.","issuer_ticker":"URGN","issuer_name_source":null,"issuer_url":"/issuer/0001033508","owner_cik":null,"owner_name":"ProQuest Investments IV, L.P.; SCHREIBER ALAIN; ProQuest Associates IV LLC; Moorin Jay","owner_display_name":"ProQuest Investments IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Ordinary Shares, par value NIS 0.01 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":177807.0,"shares_display":"177,807","price_per_share":40.51,"price_display":"40.51","price_state":"stated","total_value":7202961.57,"total_display":"7,202,961.57","total_whole":"7,202,962","shares_owned_after":1242031.0,"shares_owned_after_display":"1,242,031","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-28","filed_date":"2017-11-29","scope":"insider"},{"id":4693588,"accession":"0000932440-17-000088","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000932440-17-000088","line_url":"/filing/0000932440-17-000088#line-1","is_derivative":false,"issuer_cik":"0001033508","issuer_name":"UroGen Pharma Ltd.","issuer_ticker":"URGN","issuer_name_source":null,"issuer_url":"/issuer/0001033508","owner_cik":null,"owner_name":"ProQuest Investments IV, L.P.; SCHREIBER ALAIN; ProQuest Associates IV LLC; Moorin Jay","owner_display_name":"ProQuest Investments IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Ordinary Shares, par value NIS 0.01 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31491.0,"shares_display":"31,491","price_per_share":41.12,"price_display":"41.12","price_state":"stated","total_value":1294909.92,"total_display":"1,294,909.92","total_whole":"1,294,910","shares_owned_after":1419838.0,"shares_owned_after_display":"1,419,838","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-27","filed_date":"2017-11-29","scope":"insider"},{"id":4070418,"accession":"0000932440-17-000034","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000932440-17-000034","line_url":"/filing/0000932440-17-000034","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Investments IV, L.P.; Moorin Jay; SCHREIBER ALAIN; ProQuest Associates IV LLC","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54180.0,"shares_display":"54,180","price_per_share":88.38098837209303,"price_display":"88.38","price_state":"stated","total_value":4788481.95,"total_display":"4,788,481.95","total_whole":"4,788,482","shares_owned_after":9738.0,"shares_owned_after_display":"9,738","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-04-25","filed_date":"2017-04-27","scope":"insider","n_lines":2},{"id":4569096,"accession":"0000932440-17-000032","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000932440-17-000032","line_url":"/filing/0000932440-17-000032#line-3","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Investments IV, L.P.; Moorin Jay; ProQuest Associates IV LLC; SCHREIBER ALAIN","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61420.0,"shares_display":"61,420","price_per_share":83.13,"price_display":"83.13","price_state":"stated","total_value":5105844.6,"total_display":"5,105,844.60","total_whole":"5,105,845","shares_owned_after":3584087.0,"shares_owned_after_display":"3,584,087","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-04-03","filed_date":"2017-04-03","scope":"insider"},{"id":4569091,"accession":"0000932440-17-000032","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000932440-17-000032","line_url":"/filing/0000932440-17-000032#line-2","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Investments IV, L.P.; Moorin Jay; ProQuest Associates IV LLC; SCHREIBER ALAIN","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23689.0,"shares_display":"23,689","price_per_share":83.02,"price_display":"83.02","price_state":"stated","total_value":1966660.78,"total_display":"1,966,660.78","total_whole":"1,966,661","shares_owned_after":3645507.0,"shares_owned_after_display":"3,645,507","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-31","filed_date":"2017-04-03","scope":"insider"},{"id":4569087,"accession":"0000932440-17-000032","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000932440-17-000032","line_url":"/filing/0000932440-17-000032#line-1","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Investments IV, L.P.; Moorin Jay; ProQuest Associates IV LLC; SCHREIBER ALAIN","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6223.0,"shares_display":"6,223","price_per_share":83.0,"price_display":"83.00","price_state":"stated","total_value":516509.0,"total_display":"516,509.00","total_whole":"516,509","shares_owned_after":3669196.0,"shares_owned_after_display":"3,669,196","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-30","filed_date":"2017-04-03","scope":"insider"},{"id":4483707,"accession":"0000932440-17-000030","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000932440-17-000030","line_url":"/filing/0000932440-17-000030","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Associates IV LLC; SCHREIBER ALAIN; ProQuest Investments IV, L.P.; Moorin Jay","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60855.0,"shares_display":"60,855","price_per_share":83.01,"price_display":"83.01","price_state":"stated","total_value":5051573.55,"total_display":"5,051,573.55","total_whole":"5,051,574","shares_owned_after":3675419.0,"shares_owned_after_display":"3,675,419","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-29","filed_date":"2017-03-29","scope":"insider","n_lines":3},{"id":4483698,"accession":"0000932440-17-000030","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000932440-17-000030","line_url":"/filing/0000932440-17-000030#line-4","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Associates IV LLC; SCHREIBER ALAIN; ProQuest Investments IV, L.P.; Moorin Jay","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6182.0,"shares_display":"6,182","price_per_share":83.02,"price_display":"83.02","price_state":"stated","total_value":513229.64,"total_display":"513,229.64","total_whole":"513,230","shares_owned_after":3734174.0,"shares_owned_after_display":"3,734,174","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-28","filed_date":"2017-03-29","scope":"insider"},{"id":4483695,"accession":"0000932440-17-000030","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000932440-17-000030","line_url":"/filing/0000932440-17-000030","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Associates IV LLC; SCHREIBER ALAIN; ProQuest Investments IV, L.P.; Moorin Jay","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39431.0,"shares_display":"39,431","price_per_share":83.0,"price_display":"83.00","price_state":"stated","total_value":3272773.0,"total_display":"3,272,773.00","total_whole":"3,272,773","shares_owned_after":3740356.0,"shares_owned_after_display":"3,740,356","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-27","filed_date":"2017-03-29","scope":"insider","n_lines":3},{"id":4393637,"accession":"0000932440-17-000020","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000932440-17-000020","line_url":"/filing/0000932440-17-000020#line-2","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Associates IV LLC; SCHREIBER ALAIN; Moorin Jay; ProQuest Financial LLC; ProQuest Investments IV, L.P.","owner_display_name":"ProQuest Associates IV LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":700.0,"shares_display":"700","price_per_share":83.01,"price_display":"83.01","price_state":"stated","total_value":58107.0,"total_display":"58,107.00","total_whole":"58,107","shares_owned_after":3778087.0,"shares_owned_after_display":"3,778,087","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-23","filed_date":"2017-03-23","scope":"insider"},{"id":4393632,"accession":"0000932440-17-000020","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000932440-17-000020","line_url":"/filing/0000932440-17-000020#line-1","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Associates IV LLC; SCHREIBER ALAIN; Moorin Jay; ProQuest Financial LLC; ProQuest Investments IV, L.P.","owner_display_name":"ProQuest Associates IV LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":83.1,"price_display":"83.10","price_state":"stated","total_value":41550.0,"total_display":"41,550.00","total_whole":"41,550","shares_owned_after":3778787.0,"shares_owned_after_display":"3,778,787","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-21","filed_date":"2017-03-23","scope":"insider"},{"id":4218882,"accession":"0000932440-17-000018","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000932440-17-000018","line_url":"/filing/0000932440-17-000018#line-3","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"Moorin Jay; ProQuest Financial LLC; ProQuest Associates IV LLC; ProQuest Investments IV, L.P.; SCHREIBER ALAIN","owner_display_name":"Moorin Jay","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51883.0,"shares_display":"51,883","price_per_share":82.1,"price_display":"82.10","price_state":"stated","total_value":4259594.3,"total_display":"4,259,594.30","total_whole":"4,259,594","shares_owned_after":3779287.0,"shares_owned_after_display":"3,779,287","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-20","filed_date":"2017-03-20","scope":"insider"},{"id":4218877,"accession":"0000932440-17-000018","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000932440-17-000018","line_url":"/filing/0000932440-17-000018#line-2","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"Moorin Jay; ProQuest Financial LLC; ProQuest Associates IV LLC; ProQuest Investments IV, L.P.; SCHREIBER ALAIN","owner_display_name":"Moorin Jay","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0,001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38997.0,"shares_display":"38,997","price_per_share":82.01,"price_display":"82.01","price_state":"stated","total_value":3198143.97,"total_display":"3,198,143.97","total_whole":"3,198,144","shares_owned_after":3831170.0,"shares_owned_after_display":"3,831,170","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-17","filed_date":"2017-03-20","scope":"insider"},{"id":4218871,"accession":"0000932440-17-000018","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000932440-17-000018","line_url":"/filing/0000932440-17-000018#line-1","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"Moorin Jay; ProQuest Financial LLC; ProQuest Associates IV LLC; ProQuest Investments IV, L.P.; SCHREIBER ALAIN","owner_display_name":"Moorin Jay","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9120.0,"shares_display":"9,120","price_per_share":82.08,"price_display":"82.08","price_state":"stated","total_value":748569.6,"total_display":"748,569.60","total_whole":"748,570","shares_owned_after":3870167.0,"shares_owned_after_display":"3,870,167","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-03-16","filed_date":"2017-03-20","scope":"insider"},{"id":4139577,"accession":"0000932440-17-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000932440-17-000002","line_url":"/filing/0000932440-17-000002#line-1","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Associates IV LLC; ProQuest Investments IV, L.P.; SCHREIBER ALAIN; Moorin Jay","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":65114.0,"shares_display":"65,114","price_per_share":85.16,"price_display":"85.16","price_state":"stated","total_value":5545108.24,"total_display":"5,545,108.24","total_whole":"5,545,108","shares_owned_after":3879287.0,"shares_owned_after_display":"3,879,287","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-01-04","filed_date":"2017-01-06","scope":"insider"},{"id":3160434,"accession":"0000932440-16-000526","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000932440-16-000526","line_url":"/filing/0000932440-16-000526#line-7","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; SCHREIBER ALAIN; Moorin Jay; ProQuest Investments IV, L.P.; ProQuest Associates IV LLC","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15551.0,"shares_display":"15,551","price_per_share":85.0,"price_display":"85.00","price_state":"stated","total_value":1321835.0,"total_display":"1,321,835.00","total_whole":"1,321,835","shares_owned_after":3944401.0,"shares_owned_after_display":"3,944,401","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-11","filed_date":"2016-11-14","scope":"insider"},{"id":3160424,"accession":"0000932440-16-000526","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000932440-16-000526","line_url":"/filing/0000932440-16-000526","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; SCHREIBER ALAIN; Moorin Jay; ProQuest Investments IV, L.P.; ProQuest Associates IV LLC","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18935.0,"shares_display":"18,935","price_per_share":85.2796303142329,"price_display":"85.28","price_state":"stated","total_value":1614769.8,"total_display":"1,614,769.80","total_whole":"1,614,770","shares_owned_after":3961919.0,"shares_owned_after_display":"3,961,919","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-10","filed_date":"2016-11-14","scope":"insider","n_lines":6},{"id":2720504,"accession":"0000932440-16-000521","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000932440-16-000521","line_url":"/filing/0000932440-16-000521","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"Moorin Jay; ProQuest Financial LLC; SCHREIBER ALAIN; ProQuest Associates IV LLC; ProQuest Investments IV, L.P.","owner_display_name":"Moorin Jay","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":148800.0,"shares_display":"148,800","price_per_share":79.42248084677419,"price_display":"79.42","price_state":"stated","total_value":11818065.15,"total_display":"11,818,065.15","total_whole":"11,818,065","shares_owned_after":3977287.0,"shares_owned_after_display":"3,977,287","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-09","filed_date":"2016-11-09","scope":"insider","n_lines":6},{"id":2720473,"accession":"0000932440-16-000521","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000932440-16-000521","line_url":"/filing/0000932440-16-000521#line-1","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"Moorin Jay; ProQuest Financial LLC; SCHREIBER ALAIN; ProQuest Associates IV LLC; ProQuest Investments IV, L.P.","owner_display_name":"Moorin Jay","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5030.0,"shares_display":"5,030","price_per_share":75.39,"price_display":"75.39","price_state":"stated","total_value":379211.7,"total_display":"379,211.70","total_whole":"379,212","shares_owned_after":4126087.0,"shares_owned_after_display":"4,126,087","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-07","filed_date":"2016-11-09","scope":"insider"},{"id":2544994,"accession":"0000932440-16-000508","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000932440-16-000508","line_url":"/filing/0000932440-16-000508#line-5","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"SCHREIBER ALAIN; ProQuest Financial LLC; ProQuest Investments IV, L.P.; ProQuest Associates IV LLC; Moorin Jay","owner_display_name":"SCHREIBER ALAIN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":46170.0,"shares_display":"46,170","price_per_share":75.0,"price_display":"75.00","price_state":"stated","total_value":3462750.0,"total_display":"3,462,750.00","total_whole":"3,462,750","shares_owned_after":4181446.0,"shares_owned_after_display":"4,181,446","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-04","filed_date":"2016-11-04","scope":"insider"},{"id":2544991,"accession":"0000932440-16-000508","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000932440-16-000508","line_url":"/filing/0000932440-16-000508","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"SCHREIBER ALAIN; ProQuest Financial LLC; ProQuest Investments IV, L.P.; ProQuest Associates IV LLC; Moorin Jay","owner_display_name":"SCHREIBER ALAIN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":199600.0,"shares_display":"199,600","price_per_share":70.10338121242485,"price_display":"70.10","price_state":"stated","total_value":13992634.89,"total_display":"13,992,634.89","total_whole":"13,992,635","shares_owned_after":4227616.0,"shares_owned_after_display":"4,227,616","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-02","filed_date":"2016-11-04","scope":"insider","n_lines":4},{"id":2363505,"accession":"0000932440-16-000495","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000932440-16-000495","line_url":"/filing/0000932440-16-000495#line-1","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; ProQuest Associates IV LLC; ProQuest Investments IV, L.P.; SCHREIBER ALAIN; Moorin Jay","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22100.0,"shares_display":"22,100","price_per_share":70.06,"price_display":"70.06","price_state":"stated","total_value":1548326.0,"total_display":"1,548,326.00","total_whole":"1,548,326","shares_owned_after":4373987.0,"shares_owned_after_display":"4,373,987","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-09-30","filed_date":"2016-10-04","scope":"insider"},{"id":2133388,"accession":"0000932440-16-000493","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000932440-16-000493","line_url":"/filing/0000932440-16-000493#line-1","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"Moorin Jay; ProQuest Investments IV, L.P.; ProQuest Associates IV LLC; SCHREIBER ALAIN; ProQuest Financial LLC","owner_display_name":"Moorin Jay","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":77900.0,"shares_display":"77,900","price_per_share":70.04,"price_display":"70.04","price_state":"stated","total_value":5456116.0,"total_display":"5,456,116.00","total_whole":"5,456,116","shares_owned_after":4396087.0,"shares_owned_after_display":"4,396,087","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-09-29","filed_date":"2016-09-30","scope":"insider"},{"id":3108586,"accession":"0000932440-16-000485","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000932440-16-000485","line_url":"/filing/0000932440-16-000485","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Associates IV LLC; ProQuest Investments IV, L.P.; SCHREIBER ALAIN; ProQuest Financial LLC; Moorin Jay","owner_display_name":"ProQuest Associates IV LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":99795.0,"shares_display":"99,795","price_per_share":66.16980840723483,"price_display":"66.17","price_state":"stated","total_value":6603416.03,"total_display":"6,603,416.03","total_whole":"6,603,416","shares_owned_after":4475785.0,"shares_owned_after_display":"4,475,785","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-09-21","filed_date":"2016-09-23","scope":"insider","n_lines":4},{"id":2821234,"accession":"0000932440-16-000471","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0000932440-16-000471","line_url":"/filing/0000932440-16-000471","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; Moorin Jay; ProQuest Associates IV LLC; SCHREIBER ALAIN; ProQuest Investments IV, L.P.","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34086.0,"shares_display":"34,086","price_per_share":62.33,"price_display":"62.33","price_state":"stated","total_value":2124580.38,"total_display":"2,124,580.38","total_whole":"2,124,580","shares_owned_after":4572934.0,"shares_owned_after_display":"4,572,934","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-09-08","filed_date":"2016-09-08","scope":"insider","n_lines":3},{"id":2821216,"accession":"0000932440-16-000471","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000932440-16-000471","line_url":"/filing/0000932440-16-000471#line-7","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; Moorin Jay; ProQuest Associates IV LLC; SCHREIBER ALAIN; ProQuest Investments IV, L.P.","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11345.0,"shares_display":"11,345","price_per_share":62.26,"price_display":"62.26","price_state":"stated","total_value":706339.7,"total_display":"706,339.70","total_whole":"706,340","shares_owned_after":4606730.0,"shares_owned_after_display":"4,606,730","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-09-07","filed_date":"2016-09-08","scope":"insider"},{"id":2821212,"accession":"0000932440-16-000471","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000932440-16-000471","line_url":"/filing/0000932440-16-000471#line-6","is_derivative":false,"issuer_cik":"0000827871","issuer_name":"EAGLE PHARMACEUTICALS, INC.","issuer_ticker":"EGRX","issuer_name_source":null,"issuer_url":"/issuer/0000827871","owner_cik":null,"owner_name":"ProQuest Financial LLC; Moorin Jay; ProQuest Associates IV LLC; SCHREIBER ALAIN; ProQuest Investments IV, L.P.","owner_display_name":"ProQuest Financial LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75.0,"shares_display":"75","price_per_share":62.26,"price_display":"62.26","price_state":"stated","total_value":4669.5,"total_display":"4,669.50","total_whole":"4,670","shares_owned_after":30452.0,"shares_owned_after_display":"30,452","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-09-07","filed_date":"2016-09-08","scope":"insider"}],"collapsed":true,"next_cursor":"2016-09-07|2821212","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001668243","name":"UroGen Pharma Ltd.","url":"/issuer/0001668243","role":"Ten percent owner","n_filings":1,"first_seen":"2017-11-29","last_seen":"2017-11-29"},{"type":"issuer","type_label":"ISSUER","cik":"0000827871","name":"EAGLE PHARMACEUTICALS, INC.","url":"/issuer/0000827871","role":"Ten percent owner","n_filings":17,"first_seen":"2014-02-20","last_seen":"2017-04-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001261249","name":"AGILE THERAPEUTICS INC","url":"/issuer/0001261249","role":"Ten percent owner","n_filings":3,"first_seen":"2014-06-02","last_seen":"2016-01-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001437786","name":"Immune Design Corp.","url":"/issuer/0001437786","role":"Ten percent owner","n_filings":12,"first_seen":"2014-07-31","last_seen":"2015-05-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001070336","name":"ACHILLION PHARMACEUTICALS INC","url":"/issuer/0001070336","role":"Ten percent owner","n_filings":1,"first_seen":"2009-12-18","last_seen":"2009-12-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001431819","retrieved_at":"2026-08-23T18:41:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}